At EWMA, we presented the latest clinical results for Premotiv® dressing designed to prevent infection while supporting wound healing.

A randomized controlled trial published in the Journal of Wound Care demonstrated that Premotiv® dressing is both safe and effective in the treatment of diabetic foot ulcers. After one week of active treatment, wound area decreased by 43% in the Premotiv® group compared to 13% in the Ag+ dressing group.

You can access the abstract of the publication here: A randomized controlled trial published in the Journal of Wound Care

For your convenience, we have also summarized the key clinical and in vitro findings here.

We are currently progressing towards CE marking and expect Premotiv® dressing to become commercially available in Europe around the end of 2026.